Media headlines about Bioptix (NASDAQ:BIOP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioptix earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 46.262870447471 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Bioptix (BIOP) traded up 24.903% during midday trading on Monday, hitting $6.445. 66,703 shares of the stock were exchanged. Bioptix has a 12-month low of $3.02 and a 12-month high of $7.24. The company’s market cap is $34.82 million. The firm has a 50-day moving average price of $4.16 and a 200-day moving average price of $4.16.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at

About Bioptix

Bioptix, Inc, formerly Venaxis, Inc, provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered.

Insider Buying and Selling by Quarter for Bioptix (NASDAQ:BIOP)

Receive News & Stock Ratings for Bioptix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioptix Inc. and related stocks with our FREE daily email newsletter.